- UK doctors to receive medical cannabis education through Khiron
partnership with Medical Cannabis Clinicians Society ("MCCS"),
effective Q3 2020
- Expands reach of Khiron's globally recognized cloud-based
learning platform currently active in universities and institutions
in Latin America
- MCCS is an independent, clinician-led organization sharing
guidance to lead the medical cannabis conversation in the UK
- Program comprises access to Khiron's e-learning modules to help
doctors prescribe medical cannabis for priority conditions
including chronic pain, anxiety, cancer and epilepsy
- Program accelerates medical cannabis knowledge for doctors
participating in Project Twenty21, the UK's largest medical
cannabis registry
- By 2024, the UK medical cannabis market is predicted to be
worth nearly £1bn, servicing nearly 340,000 active patients
(source: Prohibition Partners)
TORONTO, Aug. 25, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced that it has signed an
agreement with Medical Cannabis Clinicians Society ("MCCS"), an
independent, clinician-led organization in the UK. Under this
agreement, Khiron will provide medical cannabis knowledge and
training through its cloud-based learning platform to participating
doctors across the United Kingdom.
The agreement is effective immediately, with first education
modules underway in Q3, 2020.
"Doctor education continues to be a core mission for Khiron.
Through this partnership with MCCS our e-learning program and
highly trained medical team will now bring our successful medical
cannabis knowledge to UK doctors so that they in turn can better
meet patient needs. A lack of doctor education has been missing in
growing the UK medical cannabis market and we are pleased to
participate in helping the medical community overcome this
barrier," comments Tejinder Virk,
Khiron Europe President.
The Khiron medical cannabis program begins with online courses
for MCCS participants in Q3, 2020, introducing doctors in the UK to
specific regulatory considerations, clinical evidence and research,
safety and drug interactions, clinical cases and practical
recommendations to best meet patient needs for conditions that
include chronic pain, anxiety, cancer and epilepsy. Doctors
participating in this program are also members of Project Twenty21,
the leading medical cannabis registry in the UK. Khiron is the
exclusive LatAm provider of medical cannabis to the project.
In November 2018 the UK legalized
medical cannabis, establishing a market opportunity to reach and
positively impact the lives of a population of over 66 million
according to Prohibition Partners UK Report. The UK market
opportunity remains large, with more than 1.4 million people in the
UK using 'street' cannabis for chronic pain alone (Source:
Prohibition Partners), and the number of scripts expected to
increase as access to medical cannabis expands, and doctors receive
more education on suitable applications. By 2024, the UK medical
cannabis market is predicted to be worth nearly £1bn, servicing
nearly 340,000 active patients (source: Prohibition Partners)
"We know that education is critically important in helping
doctors issue safe and effective medical cannabis prescriptions for
certain conditions. Partnering with Khiron is invaluable for MCCS
in allowing our members to work with the company's globally
validated e-learning platform to inform doctors and to improve the
quality of UK patient lives through medical cannabis," comments
Prof. Mike Barnes, Chair, Medical
Cannabis Clinicians Society.
About Medical Cannabis Clinicians Society
The
Medical Cannabis Clinicians Society is a non-profit organization
that gives clinicians the opportunity to share practical knowledge,
develop transparent and independent guidance and lead the
conversation as doctors in the sector.
As more and more doctors begin to prescribe medical cannabis for
their patients, the Society provides a confidential, independent
network for clinicians to share experiences in patient
consultation, prescribing, accessing products and treatments,
research and evidence. Members of the Society have access to
further information including prescribing guidelines, a secure
online support network and discounts to training and events. The
Medical Cannabis Clinicians Society is a community interest
company.
Visit: https://www.ukmccs.org
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both low and high THC medical cannabis products. The
Company has presence in Mexico,
Peru, Uruguay, Brazil, UK, Spain and Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage, and patient oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-expands-medical-cannabis-e-learning-platform-to-uk-market-301117272.html
SOURCE Khiron Life Sciences Corp.